非格列酮治疗糖尿病心肌病的潜力：关注机制

IF 3.4 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Diabetology & Metabolic Syndrome Pub Date : 2024-09-18 DOI:10.1186/s13098-024-01466-x

Jing Wang, Haojie Xue, Jinyu He, Li Deng, Julong Tian, Yang Jiang, Jian Feng

{"title":"非格列酮治疗糖尿病心肌病的潜力：关注机制","authors":"Jing Wang, Haojie Xue, Jinyu He, Li Deng, Julong Tian, Yang Jiang, Jian Feng","doi":"10.1186/s13098-024-01466-x","DOIUrl":null,"url":null,"abstract":"Diabetic cardiomyopathy (DCM) is a kind of myocardial disease that occurs in diabetes patients and cannot be explained by hypertensive heart disease, coronary atherosclerotic heart disease and other heart diseases. Its pathogenesis may be closely related to programmed cell death, oxidative stress, intestinal microbes and micro-RNAs. The excessive activation of mineralocorticoid receptors (MR) in DCM can cause damage to the heart and kidneys. The third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, can effectively block MR, thus playing a role in protecting the heart and kidneys. This review mainly introduces the classification of MRA, and the mechanism of action, applications and limitations of finerenone in DCM, in order to provide reference for the study of treatment plans for DCM patients.","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"1 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms\",\"authors\":\"Jing Wang, Haojie Xue, Jinyu He, Li Deng, Julong Tian, Yang Jiang, Jian Feng\",\"doi\":\"10.1186/s13098-024-01466-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetic cardiomyopathy (DCM) is a kind of myocardial disease that occurs in diabetes patients and cannot be explained by hypertensive heart disease, coronary atherosclerotic heart disease and other heart diseases. Its pathogenesis may be closely related to programmed cell death, oxidative stress, intestinal microbes and micro-RNAs. The excessive activation of mineralocorticoid receptors (MR) in DCM can cause damage to the heart and kidneys. The third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, can effectively block MR, thus playing a role in protecting the heart and kidneys. This review mainly introduces the classification of MRA, and the mechanism of action, applications and limitations of finerenone in DCM, in order to provide reference for the study of treatment plans for DCM patients.\",\"PeriodicalId\":11106,\"journal\":{\"name\":\"Diabetology & Metabolic Syndrome\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetology & Metabolic Syndrome\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13098-024-01466-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology & Metabolic Syndrome","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13098-024-01466-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

糖尿病心肌病（DCM）是发生在糖尿病患者身上的一种心肌疾病，无法用高血压性心脏病、冠状动脉粥样硬化性心脏病和其他心脏病来解释。其发病机制可能与程序性细胞死亡、氧化应激、肠道微生物和微核糖核酸密切相关。DCM 中矿物皮质激素受体（MR）的过度激活会对心脏和肾脏造成损害。第三代非甾体类矿物皮质激素受体拮抗剂（MRA）非诺酮能有效阻断MR，从而起到保护心脏和肾脏的作用。本综述主要介绍了 MRA 的分类，以及非奈酮在 DCM 中的作用机制、应用和局限性，以期为研究 DCM 患者的治疗方案提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms

Diabetic cardiomyopathy (DCM) is a kind of myocardial disease that occurs in diabetes patients and cannot be explained by hypertensive heart disease, coronary atherosclerotic heart disease and other heart diseases. Its pathogenesis may be closely related to programmed cell death, oxidative stress, intestinal microbes and micro-RNAs. The excessive activation of mineralocorticoid receptors (MR) in DCM can cause damage to the heart and kidneys. The third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, can effectively block MR, thus playing a role in protecting the heart and kidneys. This review mainly introduces the classification of MRA, and the mechanism of action, applications and limitations of finerenone in DCM, in order to provide reference for the study of treatment plans for DCM patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetology & Metabolic Syndrome ENDOCRINOLOGY & METABOLISM-

CiteScore

6.20

自引率

0.00%

发文量

170

审稿时长

7.5 months

期刊介绍： Diabetology & Metabolic Syndrome publishes articles on all aspects of the pathophysiology of diabetes and metabolic syndrome. By publishing original material exploring any area of laboratory, animal or clinical research into diabetes and metabolic syndrome, the journal offers a high-visibility forum for new insights and discussions into the issues of importance to the relevant community.